Department of Neurology, Tokyo Metropolitan Neurological Hospital, Fuchu, Tokyo, Japan.
Mol Neurodegener. 2012 May 14;7:20. doi: 10.1186/1750-1326-7-20.
Despite enormous progress in elucidating the biophysics of aggregation, no cause-and-effect relationship between protein aggregation and neurodegenerative disease has been unequivocally established. Here, we derived several risk-based stochastic kinetic models that assess genotype/phenotype correlations in patients with Huntington's disease (HD) caused by the expansion of a CAG repeat. Fascinating disease-specific aspects of HD include the polyglutamine (polyQ)-length dependence of both age at symptoms onset and the propensity of the expanded polyQ protein to aggregate. In vitro, aggregation of polyQ peptides follows a simple nucleated growth polymerization pathway. Our models that reflect polyQ aggregation kinetics in a nucleated growth polymerization divided aggregate process into the length-dependent nucleation and the nucleation-dependent elongation. In contrast to the repeat-length dependent variability of age at onset, recent studies have shown that the extent of expansion has only a subtle effect on the rate of disease progression, suggesting possible differences in the mechanisms underlying the neurodegenerative process.
Using polyQ-length as an index, these procedures enabled us for the first time to establish a quantitative connection between aggregation kinetics and disease process, including onset and the rate of progression. Although the complexity of disease process in HD, the time course of striatal neurodegeneration can be precisely predicted by the mathematical model in which neurodegeneration occurs by different mechanisms for the initiation and progression of disease processes. Nucleation is sufficient to initiate neuronal loss as a series of random events in time. The stochastic appearance of nucleation in a cell population acts as the constant risk of neuronal cell damage over time, while elongation reduces the risk by nucleation in proportion to the increased extent of the aggregates during disease progression.
Our findings suggest that nucleation is a critical step in gaining toxic effects to the cell, and provide a new insight into the relationship between polyQ aggregation and neurodegenerative process in HD.
尽管在阐明聚集的生物物理学方面取得了巨大进展,但尚未明确建立蛋白质聚集与神经退行性疾病之间的因果关系。在这里,我们推导出了几种基于风险的随机动力学模型,这些模型评估了由 CAG 重复扩展引起的亨廷顿病(HD)患者的基因型/表型相关性。HD 具有引人入胜的疾病特异性方面,包括症状发作年龄和扩展的多聚谷氨酰胺(polyQ)蛋白聚集倾向的多聚谷氨酰胺(polyQ)长度依赖性。在体外,polyQ 肽的聚集遵循简单的成核生长聚合途径。我们的模型反映了成核生长聚合分裂聚合过程中的 polyQ 聚集动力学,将长度依赖性成核和成核依赖性伸长分为两部分。与发病年龄的重复长度依赖性可变性相反,最近的研究表明,扩展程度对疾病进展速度只有细微影响,这表明神经退行性过程的潜在机制可能存在差异。
使用 polyQ 长度作为指标,这些程序使我们首次能够在包括发病和进展速度在内的聚合动力学和疾病过程之间建立定量联系。尽管 HD 疾病过程复杂,但通过数学模型可以精确预测纹状体神经退行性变的时间过程,其中神经退行性变通过疾病过程的启动和进展的不同机制发生。成核足以作为一系列随机事件在时间上引发神经元丧失。在细胞群体中成核的随机出现随着时间的推移充当神经元细胞损伤的恒定风险,而伸长通过成核降低风险,与疾病进展过程中聚集体的扩展程度成比例。
我们的研究结果表明,成核是对细胞产生毒性作用的关键步骤,并为 HD 中 polyQ 聚集与神经退行性过程之间的关系提供了新的见解。